Subject: RXMD Picks Up More Publicity for Amazingly Productive 2018

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
RXMD Picks Up More Publicity for Amazingly Productive 2018
Hot Stock to WatchHot Stock to Watch

Company: Progressive Care Inc. (OTCQB: RXMD)


Price: 0.0549

Change (%): + 0.0049 (9.8)

Volume: 149,600
RXMD Chart

Progressive Care Inc. Garners News Coverage in Leading Financial Publications, Yahoo Finance and Benzinga on Its Efforts to End the Opioid Crisis

MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) - Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered news coverage in leading financial publications Yahoo Finance and Benzinga on its ongoing work towards ending the opioid epidemic.

“We are honored to have Progressive Care’s efforts toward improving the opioid crisis in such noteworthy publications,” said S. Parikh Mars, CEO of Progressive Care Inc. “We are passionate about providing the public with opioid alternatives to ensure a safer future for our patients.”

In a contributed article titled “If The Cannabis Industry Is Serious About Health Care, It Must Learn From The Opioid Crisis”, published December 14, 2018, in Benzinga, Mars focuses on the future of healthcare and the importance of making it personal and not driven by the same bottom-line logic that helped fuel the opioid crisis.

In the piece, Mars writes: “Technology should make healthcare more personal, not less,” she said. “We want it to be patient-centered care, not patient-burden care.”

Progressive Care has remained committed to taking steps to create a personal healthcare system for the public, most recently with the launch of their new proprietary tele-pharmacy software Tele-PharmCo.

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks